IUPAC name: S-(poly(tris(hydroxymethyl) acrylamidomethane) –
Compound name: FTAC8
Catalogue number: FTAC8_250MG,
Molec. Formula: C8F17CH2CH2
MW: ≈2600 g/mol
Percent Composition: na
Physical state: White powder
Purity (HPLC, 214nm): nd
Retention time (RP18 HPLC)b: tR = 11.7 min min
CMC: 0.02 mM
Exact mass: nd
Stability: Store in <-20°C freezer out of direct light
Solubility Structure: Soluble in water (1mM), methanol and DMSO
We use proprietary technology & custom-built approaches to give you the edge
CALIXAR’s FTAC8 is a rather mild detergent utilized to stabilize native membrane proteins. FTAC8 is non-ionic and therefore not susceptible to ionic strength fluctuations or pH variations. They are also well suited to stabilize many different particular membrane proteins. Due to the fluorinated chain, FTAC8 is poorly delipidating towards membrane proteins.
Our FTAC8 helps generate lipid detergent mixed micelles and protein detergent micelles. FTAC8 also allows for the stabilization of native and functional membrane proteins. It is also used as a protein chaperone to inject membrane proteins into liposomes.
CALIXAR’s FTAC8 is provided in powder form and is generally used in an aqueous solution or buffer. It can also be mixed within biological materials (biological membranes).
CALIXAR’s FTAC8 is non-ionic detergent and therefore is not susceptible to ionic strength variations or pH fluctuations. It is also able to stabilize specific membrane proteins due to the fluorinated chain. FTAC8 does not solubilize the lipid membrane.
CALIXAR’s FTAC8 is a leading-quality detergent / reagent principally used in research and drug discovery projects. Our structural studies and are adapted for use in pharmaceutical and biotechnology companies, as well as for life science academic teams (biochemists, structural biologists, virologists, pharmacologists).
- Antibodies (including nanobodies, scaffold proteins, aptamers)
- Small molecules
- 3D Structures (cryoEM, XRay crystallography, NMR, SANS, SAXS)
- Drug discovery (Screening: HTS, FBDD, SBDD; Hit and lead validation)
- Antibody discovery (Immunization and display technologies)
- Clinical stage (drug validation on reliable native DDLAC)